Unit Price: ৳ 85.00 (1 x 7: ৳ 595.00)
Strip Price: ৳ 595.00

Indications

Furonaaf-CV is indicated for the treatment of infections caused by sensitive bacteria.
  • Pharyngitis/Tonsillitis caused by Streptococcus pyogenes.
  • Acute Bacterial Otitis Media caused by Streptococcus pneumoniae, Haemophilus influenzae, Moraxella catarrhalis (beta-lactamase producing strains) or Streptococcus pyogenes.
  • Acute bacterial maxillary sinusitis caused by Streptococcus pneumoniae or Haemophilus influenzae (non beta-lactamase producing strains)
  • Lower respiratory tract infections including pneumoniae, caused by Streptococcus pneumoniae, Haemophilus influenzae (including beta lactamase-producing strains), Klebsiella spp., Staphylococcus aureus (penicillinase- and non-penicillinase-producing strains), Streptococcus pyogenes, E. coli.
  • Acute bacterial exacerbation of chronic bronchitis and secondary bacterial infections of Acute bronchitis caused by Streptococcus pneumoniae, Haemophilus influenzae (beta-lactamase negative strains) or Haemophilus parainfluenzae (beta-lactamase negative strains).
  • Uncomplicated skin and skin-structure infections caused by Staphylococcus aureus (including beta-lactamase producing strains) or Streptococcus pyogenes.
  • Uncomplicated urinary tract infections caused by E.coli or Klebsiella pneumoniae.
  • Bone and Joint Infections caused by Staphylococcus aureus (penicillinase- and non-penicillinase-producing strains).
  • Uncomplicated Gonorrhoea caused by penicillinase-producing and non-penicillinase producing strains of Neisseria gonorrhoeae.
  • Early Lyme Disease (erythema migrans) caused by Borrelia burgdorferi.
  • Septicemia caused by Staphylococcus aureus, Streptococcus pneumoniae, E.coli, Haemophilus influenzae (including ampicillin-resistant strains) & Klebsiella spp.
  • Meningitis caused by Streptococcus pneumoniae, Haemophilus influenzae (including ampicillin-resistant strains), Neisseria meningitidis & Staphylococcus aureus (penicillinase and non-penicillinase producing strains)
  • Switch therapy (Injectable to oral)

Pharmacology

Cefuroxime is a bactericidal second generation cephalosporin antibiotic which is active against a wide range of Gram-positive and Gram-negative susceptible organisms including many beta-lactamase producing strains. Cefuroxime inhibits bacterial cell wall synthesis by interfering with the transpeptidation process.

Clavulanic acid is a naturally derived beta lactamase inhibitor produced by Streptomyces clavuligerus. It has similar structure to beta lactam antibiotics which binds irreversibly to beta-lactamase enzymes and inactivates them. Clavulanic acid gives protection of Cefuroxime from degradation by beta lactamase enzymes and provides a solution for the treatment of bacterial infections caused by beta lactam resistant bacteria.

Dosage & Administration

Adolescents and adults (13 years and older)-
  • Pharyngitis/tonsillitis: 250 mg b.i.d. for 5-10 days
  • Acute bacterial maxillary sinusitis: 250 mg b.i.d. for 10 days
  • Acute bacterial exacerbation of chronic bronchitis: 250-500 mg b.i.d. for 10 days
  • Secondary bacterial infections of acute bronchitis: 250-500 mg b.i.d. for 5-10 days 
  • Uncomplicated skin and skin structure infections: 250-500 mg b.i.d. for 10 days
  • Uncomplicated urinary tract infections: 250 mg b.i.d. for 7-10 days
  • Uncomplicated Gonorrhoea: 1000 mg b.i.d. Single dose
  • Community acquired pneumonia: 250-500 mg b.i.d. for 5-10 days
  • MDR Typhoid Fever: 500 mg b.i.d. for 10-14 days
  • Early Lyme disease: 500 mg b.i.d. for 20 days
Paediatric Patients (3 months to 12 years)-
  • Pharyngitis/Tonsillitis: 20 mg/kg/day b.i.d for 5-10 days
  • Acute otitis media: 30 mg/kg/day b.i.d for 10 days
  • Acute bacterial maxillary sinusitis: 30 mg/kg/day b.i.d for 10 days
  • Impetigo: 30 mg/kg/day b.i.d for 10 days
Cefuroxime-Clavulanic Acid tablet may be taken without regard of food.

Interaction

Concomitant administration of probenecid with Cefuroxime-Clavulanic Acid increases the area under the serum concentration versus time curve by 50%. Drug that reduces gastric acidity may result in a lower bioavailability of Cefuroxime and tend to cancel the effect of postprandial absorption.

Contraindications

Cefuroxime-Clavulanic Acid is contraindicated in patients with known allergy to cephalosporin & in patients with Pseudomembranous Colitis.

Side Effects

Generally Cefuroxime-Clavulanic Acid is well tolerated. However, a few side effects like nausea, vomiting, diarrhea, abdominal discomfort or pain may occur. As with other broad-spectrum antibiotics, prolonged administration of Cefuroxime and Clavulanic acid combination may result in overgrowth of nonsusceptible microorganisms. Rarely (<0.2%) renal dysfunction, anaphylaxis, angioedema, pruritis, rash and serum sickness like urticaria may appear.

Pregnancy & Lactation

While all antibiotics should be avoided in the first trimester if possible. However, Cefuroxime-Clavulanic Acid can be safely used in later pregnancy to treat urinary and other infections. Cefuroxime-Clavulanic Acid is excreted into the breast milk in small quantities. However, the possibility of sensitizing the infant should be kept in mind.

Precautions & Warnings

Cefuroxime should be given with care to patients receiving concurrent treatment with potent diuretics & who has history of colitis.

Therapeutic Class

Second generation Cephalosporins

Storage Conditions

Store in a cool, dry place (below 30o C), away from light and moisture. Keep out of the reach of children.

Common Questions about Furonaaf-CV 500 mg Tablet

What is Furonaaf-CV 500 mg Tablet?

Cefuroxime is the cephalosporin antibiotic and Clavulanic acid is a beta-lactamase inhibitor. Furonaaf-CV 500 mg Tablet is indicated for the treatment of infections caused by sensitive bacteria.

What is Furonaaf-CV 500 mg Tablet used for?

Furonaaf-CV 500 mg Tablet is used to treat pharyngitis, tonsillitis, sinusitis, bronchitis, SSTI, UTI, gonorrhoea, pneumonia, typhoid fever.

How long does it take for Furonaaf-CV 500 mg Tablet to take effect?

Furonaaf-CV 500 mg Tablet starts working within 2-3 hours after taking it.

How long do the effects of this medicine last?

The effect of Furonaaf-CV 500 mg Tablet lasts for an average duration of 4-8 hours.

Furonaaf-CV 500 mg Tablet it safe to consume alcohol while taking this medicine?

Interaction with alcohol is unknown. It is advisable to consult your doctor before consumption.

Is Furonaaf-CV 500 mg Tablet a habit forming medicine?

No habit-forming tendencies were reported for Furonaaf-CV 500 mg Tablet.

Can this medicine be taken during pregnancy?

Furonaaf-CV 500 mg Tablet is safe to use in pregnancy to treat bacterial infections. However, it is recommended to use this medicine only after consulting your doctor.

Can Furonaaf-CV 500 mg Tablet be taken while breast-feeding?

Furonaaf-CV 500 mg Tablet is safe to use during breastfeeding. It enters into breast milk at low levels.

Quick Tips

  • You have been prescribed Furonaaf-CV 500 mg Tablet medicine to treat bacterial infections, even if they have developed resistance.
  • Do not skip any doses and finish the full course of treatment even if you feel better. Stopping it early may make the infection to come back and harder to treat.
  • Take it with food to avoid an upset stomach.
  • Diarrhea may occur as a side effect. Taking probiotics may help. Talk to your doctor if you notice bloody stools or develop abdominal cramps.
  • Stop taking Furonaaf-CV 500 mg Tablet and inform your doctor immediately if you develop an itchy rash, swelling of the face, throat or tongue or breathing difficulties while taking it.
  • Do not use leftover medicine for treating any infection in the future. Always consult your doctor before taking any antibiotic.